

Thomas Drner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5496294/thomas-dorner-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234 papers	16,966 citations	67 h-index	126 g-index
279 ext. papers	21,672 ext. citations	7.2 avg, IF	7.05 L-index

#	Paper	IF	Citations
234	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. <i>Computational and Structural Biotechnology Journal</i> , 2022 , 20, 471-484	6.8	0
233	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients.. <i>JCI Insight</i> , 2022 ,	9.9	4
232	Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.. <i>New England Journal of Medicine</i> , 2022 , 386, 1034-1045	59.2	5
231	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus.. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
230	CD39 and CD326 Are Bona Fide Markers of Murine and Human Plasma Cells and Identify a Bone Marrow Specific Plasma Cell Subpopulation in Lupus.. <i>Frontiers in Immunology</i> , 2022 , 13, 873217	8.4	1
229	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients.. <i>Frontiers in Immunology</i> , 2022 , 13, 822885	8.4	0
228	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.. <i>Journal of Clinical Immunology</i> , 2022 , 1	5.7	1
227	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 112	5.7	1
226	B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab.. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	11
225	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).. <i>European Journal of Immunology</i> , 2021 , 51, 2708-3145	6.1	12
224	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
223	Safety and efficacy of subcutaneous ivalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet, The</i> , 2021 ,	40	7
222	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	17
221	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. <i>European Journal of Immunology</i> , 2021 ,	6.1	2
220	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1490-1504	4.7	13
219	SARS-CoV-2 in severe COVID-19 induces a TGF- β -dominated chronic immune response that does not target itself. <i>Nature Communications</i> , 2021 , 12, 1961	17.4	41
218	BTLA Expression and Function Are Impaired on SLE B Cells. <i>Frontiers in Immunology</i> , 2021 , 12, 667991	8.4	3

217	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5397-5407	3.9	10
216	POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 593-594	2.4	
215	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021 , 7,	5.9	3
214	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021 , 6,	2.8	93
213	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021 , 12, 690698	8.4	28
212	Viscoelastic testing reveals normalization of the coagulation profile 12 weeks after severe COVID-19. <i>Scientific Reports</i> , 2021 , 11, 13325	4.9	2
211	Response to: 'Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus' by Wang. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e193	2.4	
210	Response to: 'New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion' by Sacre. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e191	2.4	2
209	Response to: 'European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view' by Infantino. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e189	2.4	21
208	B cells in SLE 2021 , 131-138		1
207	Treatment of Sjögren's syndrome: current therapy and future directions. <i>Rheumatology</i> , 2021 , 60, 2066-2074	9.4	16
206	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
205	Toll-like receptor signalling in B cells during systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 98-108	8.1	40
204	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
203	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021 , 38, 265-284	4.7	0
202	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
201	Deep Phenotyping of CD11c B Cells in Systemic Autoimmunity and Controls. <i>Frontiers in Immunology</i> , 2021 , 12, 635615	8.4	7
200	Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 592-597	5.3	2

199	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Aringer. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	0
198	Vaccine-Induced Thrombocytopenia with Severe Headache. <i>New England Journal of Medicine</i> , 2021 , 385, 2103-2105	59.2	28
197	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives.. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	1
196	Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. <i>Critical Care</i> , 2020 , 24, 676	10.8	36
195	Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. <i>Rheumatology</i> , 2020 , 59, 3435-3442	3.9	10
194	Human CD27+ memory B cells colonize a superficial follicular zone in the palatine tonsils with similarities to the spleen. A multicolor immunofluorescence study of lymphoid tissue. <i>PLoS ONE</i> , 2020 , 15, e0229778	3.7	4
193	SLE classification criteria items are not dependent on current activity but may accumulate over time. Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
192	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 155-166	8.1	596
191	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 860-861	9.5	
190	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1404	9.5	
189	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 3-18	2.4	139
188	EZH2 Inhibition in B Cell Subsets: Comment on the Article by Rohraff et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 371-373	9.5	1
187	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 695-696	9.5	1
186	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	14
185	Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2020 , 11, 572475	8.4	5
184	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020 , 6,	5.9	10
183	Role for antimalarials in the management of COVID-19. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 449-457	5.7	5
182	Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. <i>RMD Open</i> , 2020 , 6,	5.9	5

181	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
180	Gastrointestinal SLE involvement in SLE classification. Response to: "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus" by Aringer ' by Cui. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	16
179	Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e44	2.4	3
178	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72, 1820-1826	4.7	16
177	Human IgA-Expressing Bone Marrow Plasma Cells Characteristically Upregulate Programmed Cell Death Protein-1 Upon B Cell Receptor Stimulation. <i>Frontiers in Immunology</i> , 2020 , 11, 628923	8.4	2
176	Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 228-236	2.2	3
175	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
174	Difference between SLE classification and diagnosis and importance of attribution. Response to: 'Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?' by Chi. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	3
173	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35
172	Novel paradigms in systemic lupus erythematosus. <i>Lancet, The</i> , 2019 , 393, 2344-2358	4.0	186
171	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1296-1304	2.4	312
170	Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 641-647	2.4	69
169	Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1539-1544	9.5	15
168	B cell subset distribution in human bone marrow is stable and similar in left and right femur: An instructive case. <i>PLoS ONE</i> , 2019 , 14, e0212525	3.7	0
167	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019 , 10, 29	8.4	8
166	Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019 , 71, 91-98	9.5	60
165	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
164	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488

163	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019 , 10, 2136	8.4	24
162	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e001064	5.9	24
161	Pathogenic memory plasma cells in autoimmunity. <i>Current Opinion in Immunology</i> , 2019 , 61, 86-91	7.8	14
160	Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 175-184	5.3	11
159	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019 , 6, e000342	4.6	8
158	Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	
157	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019 , 46, 721-726	4.1	29
156	Reply. <i>Arthritis Care and Research</i> , 2019 , 71, 696-697	4.7	1
155	Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRA). <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 937-945	2.2	1
154	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. <i>Arthritis and Rheumatology</i> , 2018 , 70, 763-773	9.5	31
153	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1488-1494	4.7	36
152	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 741-758	12.7	26
151	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018 , 70, 428-438	4.7	86
150	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018 , 70, 571-581	4.7	74
149	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 165-174	2.4	120
148	Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. <i>European Journal of Immunology</i> , 2018 , 48, 194-203	6.1	7
147	LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. <i>Immunity</i> , 2018 , 49, 120-133.e9	32.3	110
146	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	40	243

145	Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. <i>Journal of Immunology</i> , 2018 , 200, 3981-3992	5.3	12
144	136 Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018 , 57,	3.9	1
143	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018 , 4, e000785	5.9	21
142	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
141	High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1476-1480	2.4	33
140	Plasmablasts With a Mucosal Phenotype Contribute to Plasmacytosis in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2018-2028	9.5	17
139	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017 , 19, 37	4.9	62
138	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1	359
137	Drivers of the immunopathogenesis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 321-333	5.3	24
136	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. <i>Rheumatology</i> , 2017 , 56, 1618-1626	3.9	29
135	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1837-1844	2.4	60
134	Considering biosimilar policy 2017 , 1, 19-24		
133	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 382-9	2.4	144
132	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 137-56	5.1	83
131	Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1210-21	9.5	21
130	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 974-824		124
129	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. <i>RMD Open</i> , 2016 , 2, e000292	5.9	23
128	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163	4.6	34

127	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1945-1950	2.4	41
126	Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. <i>Journal of Cell Communication and Signaling</i> , 2016 , 10, 143-51	5.2	12
125	Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 645-657	8.1	46
124	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015 , 14, 1079-86	13.6	48
123	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015 , 54, 2230-8	3.9	150
122	CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 61	5.7	39
121	Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF- α but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. <i>Arthritis Research and Therapy</i> , 2015 , 17, 185	5.7	35
120	Biosimilars in rheumatology: current perspectives and lessons learnt. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 713-24	8.1	77
119	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 859-66	2.4	138
118	A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. <i>Blood</i> , 2015 , 125, 1739-48	2.2	113
117	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 206	5.7	7
116	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015 , 1, e000022	5.9	150
115	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015 , 1, e000037	5.9	14
114	Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 347-53	2.2	9
113	Outcome measures for primary Sjögren's syndrome: a comprehensive review. <i>Journal of Autoimmunity</i> , 2014 , 51, 51-6	15.5	55
112	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. <i>Nature</i> , 2014 , 507, 366-370	50.4	670
111	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
110	Emerging cell and cytokine targets in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 77-88.1		197

109	Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. <i>Journal of Immunology</i> , 2014 , 192, 3091-100	5.3	60
108	Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. <i>Arthritis Research and Therapy</i> , 2014 , 16, 477	5.7	31
107	Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3424-35	9.5	36
106	B cells: depletion or functional modulation in rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 228-36	5.3	32
105	Immunopathogenic mechanisms of systemic autoimmune disease. <i>Lancet, The</i> , 2013 , 382, 819-31	4.0	312
104	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 322-8	2.4	134
103	CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. <i>Arthritis and Rheumatism</i> , 2013 , 65, 770-9		54
102	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72 Suppl 2, ii2-34	2.4	96
101	Antiphospholipid antibody profiling: time for a new technical approach?. <i>Autoimmunity Reviews</i> , 2012 , 11, 821-6	13.6	34
100	CD22 and autoimmune disease. <i>International Reviews of Immunology</i> , 2012 , 31, 363-78	4.6	36
99	Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2012 , 14 Suppl 5, S1	5.7	63
98	SLE in 2011: Deciphering the role of NETs and networks in SLE. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 68-70	8.1	18
97	Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 738-46	8.1	33
96	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
95	EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 968-72	2.4	264
94	Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. <i>Arthritis Research and Therapy</i> , 2011 , 13, R118	5.7	28
93	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
92	Abnormalities of B cell subsets in patients with systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2011 , 363, 187-97	2.5	95

91	In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1255-64		73
90	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011 , 13, 243	5.7	169
89	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
88	Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in pre-switch memory B cells and modulation of mutational targeting in memory B cells. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1507-10	2.4	32
87	Memory B and memory plasma cells. <i>Immunological Reviews</i> , 2010 , 237, 117-39	11.3	202
86	Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. <i>Journal of Immunology</i> , 2010 , 185, 3103-10	5.3	61
85	Current aspects of anti-CD20 therapy in rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2010 , 10, 316-21	5.1	23
84	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010 , 12, R204	5.7	69
83	Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. <i>Blood</i> , 2010 , 116, 5181-90	2.2	79
82	Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. <i>Pharmacology & Therapeutics</i> , 2010 , 125, 464-75	13.9	77
81	What do we know about memory B cells in primary Sjögren's syndrome?. <i>Autoimmunity Reviews</i> , 2010 , 9, 600-3	13.6	23
80	Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome. <i>Journal of Rheumatology</i> , 2009 , 36, 2694-703	4.1	11
79	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009 , 9, 82-9	13.6	54
78	Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. <i>Clinical Immunology</i> , 2009 , 130, 199-212	9	49
77	Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2284-93		30
76	Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2009 , 11, 255	5.7	10
75	B cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2009 , 11, 247	5.7	99
74	B-cell-directed therapies for autoimmune disease. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 433-41	8.1	130

73	Anticytokine therapy impacting on B cells in autoimmune diseases. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 205-10	5.3	24
72	Blood-borne human plasma cells in steady state are derived from mucosal immune responses. <i>Blood</i> , 2009 , 113, 2461-9	2.2	178
71	The Role of B Cells in Rheumatoid Arthritis 2009 , 97-106		1
70	New approaches of B-cell-directed therapy: beyond rituximab. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 263-8	5.3	68
69	Plasma cell differentiation and survival. <i>Current Opinion in Immunology</i> , 2008 , 20, 162-9	7.8	148
68	Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1566-75		141
67	Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1762-73		204
66	High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2007 , 136, 309-14	4.5	95
65	B-cell targeting: a novel approach to immune intervention today and tomorrow. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1287-99	5.4	30
64	Antibodies and B cell memory in viral immunity. <i>Immunity</i> , 2007 , 27, 384-92	32.3	186
63	B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. <i>Arthritis Research and Therapy</i> , 2007 , 9, 218	5.7	103
62	Targeting CD22 as a strategy for treating systemic autoimmune diseases. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 953-9	2.9	26
61	Phenotypic analysis of B-cells and plasma cells. <i>Methods in Molecular Medicine</i> , 2007 , 136, 3-18		7
60	Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. <i>Autoimmunity Reviews</i> , 2006 , 5, 437-42	13.6	58
59	Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2377-86		246
58	Implant-related inflammatory arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 53-6; quiz 57		16
57	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006 , 8, R74	5.7	228
56	Contribution of B Cells to Autoimmune Pathogenesis 2006 , 461-501		

55	Adaptation of humoral memory. <i>Immunological Reviews</i> , 2006 , 211, 295-302	11.3	67
54	Competence and competition: the challenge of becoming a long-lived plasma cell. <i>Nature Reviews Immunology</i> , 2006 , 6, 741-50	36.5	722
53	Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. <i>Journal of rheumatology Supplement, The</i> , 2006 , 77, 3-11		52
52	Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. <i>Blood</i> , 2005 , 105, 1614-21	2.2	324
51	Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2005 , 7, R1001-137	15.7	89
50	Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. <i>Arthritis Research</i> , 2005 , 7, R714-24		42
49	Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 558-65	5.3	79
48	Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2109-19		57
47	Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. <i>Clinical and Experimental Medicine</i> , 2005 , 4, 159-69	4.9	29
46	Antibodies against protein Z and fetal loss: current perspectives. <i>Clinical and Experimental Medicine</i> , 2005 , 5, 50-4	4.9	4
45	Cryopreserved human B cells as an alternative source for single cell mRNA analysis. <i>Cell and Tissue Banking</i> , 2005 , 6, 299-308	2.2	7
44	Selecting B cells and plasma cells to memory. <i>Journal of Experimental Medicine</i> , 2005 , 201, 497-9	16.6	33
43	Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1897-908		67
42	Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3211-20		157
41	Autoantibodies in normals--the value of predicting rheumatoid arthritis. <i>Arthritis Research</i> , 2004 , 6, 282-4		10
40	Rheumatoid factor revisited. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 246-53	5.3	154
39	New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 563-70	5.3	57
38	The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 246-52	5.3	113

37	Correlation between circulating CD27 ^{high} plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1332-42		259
36	Development of systemic lupus erythematosus in a patient with congenital heart block. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2697-8; discussion 2699		4
35	Aberrant activation of B cells in patients with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , 2003 , 987, 246-8	6.5	19
34	A serologic marker for fetal risk of congenital heart block. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1233-41		113
33	Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2160-71		201
32	Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. <i>Blood</i> , 2002 , 100, 3419-22	2.2	37
31	Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome. <i>Arthritis Research</i> , 2002 , 4, 360-71		35
30	Immunoglobulin repertoire analysis provides new insights into the immunopathogenesis of Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2002 , 1, 119-24	13.6	30
29	Immunoglobulin V kappa light chain gene analysis in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001 , 44, 626-37		20
28	Immunoglobulin V lambda light chain gene usage in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2620-32		22
27	Immunoglobulin variable-region gene usage in systemic autoimmune diseases. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2715-27		39
26	Smaller role for pol eta?. <i>Nature Immunology</i> , 2001 , 2, 982-4	19.1	8
25	Perturbations in the impact of mutational activity on V lambda genes in systemic lupus erythematosus. <i>Arthritis Research</i> , 2001 , 3, 368-74		14
24	Significance of autoantibodies in neonatal lupus erythematosus. <i>International Archives of Allergy and Immunology</i> , 2000 , 123, 58-66	3.7	21
23	Targeting and selection of mutations in human V lambda rearrangements. <i>European Journal of Immunology</i> , 2000 , 30, 1597-605	6.1	30
22	The influence of CD40-CD154 interactions on the expressed human V(H) repertoire: analysis of V(H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. <i>International Immunology</i> , 2000 , 12, 767-75	4.9	25
21	Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. <i>Journal of Immunology</i> , 2000 , 165, 5970-9	5.3	477
20	Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. <i>Autoimmunity</i> , 2000 , 33, 61-76	3	19

19	Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type. <i>Arthritis and Rheumatism</i> , 1999 , 42, 697-702		54
18	Targeting and subsequent selection of somatic hypermutations in the human V kappa repertoire. <i>European Journal of Immunology</i> , 1999 , 29, 3122-32	6.1	26
17	Somatic hypermutation of V kappa J kappa rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. <i>European Journal of Immunology</i> , 1999 , 29, 4011-21	6.1	48
16	Enhanced mutational activity of V kappa gene rearrangements in systemic lupus erythematosus. <i>Clinical Immunology</i> , 1999 , 92, 188-96	9	37
15	Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. <i>Immunological Reviews</i> , 1998 , 162, 161-71	11.3	89
14	Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM+/CD5- and IgM+/CD5+ B cells. <i>European Journal of Immunology</i> , 1998 , 28, 657-68	6.1	31
13	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998 , 28, 3384-96	6.1	108
12	Similar characteristics of the CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 1998 , 102, 516-21	4.5	22
11	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands 1998 , 28, 3384		1
10	Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro (SS-A) and La(SS-B) in complete congenital heart block. <i>Journal of Autoimmunity</i> , 1995 , 8, 675-84	15.5	39
9	Detection of autoantibodies to Ro(SS-A), La(SS-B) and U1RNP in different congenital heart rhythm disorders using immunoblot and enzyme immunoassay. <i>Journal of Autoimmunity</i> , 1994 , 7, 93-106	15.5	20
8	Mobilization of tissue-resident memory CD4+ T lymphocytes and their contribution to a systemic secondary immune reaction		2
7	Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients		2
6	In severe COVID-19, SARS-CoV-2 induces a chronic, TGF-β-dominated adaptive immune response		6
5	Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients		1
4	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis		4
3	B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab		3
2	Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota		1

1	B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant Recipients	1
---	---	---